PRIMARY HUMAN-IMMUNODEFICIENCY-VIRUS TYPE-1 INFECTION - REVIEW OF PATHOGENESIS AND EARLY TREATMENT INTERVENTION IN HUMANS AND ANIMAL RETROVIRUS INFECTIONS

被引:123
作者
NIU, MT
STEIN, DS
SCHNITTMAN, SM
机构
[1] Division of AIDS, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MY
关键词
D O I
10.1093/infdis/168.6.1490
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Primary human immunodeficiency virus type 1 (HIV-1) infection can present clinically as the abrupt onset of a febrile illness resembling acute mononucleosis. The symptoms coincide with high titers of culturable plasma viremia, cell-associated virus, and antigenemia, which rapidly decrease coincident with the emergence of detectable HIV-specific antibody and HIV-specific cytotoxic T lymphocytes. This article reviews the human and animal model data on the virologic and immunologic events that occur during primary HIV-1 and animal retrovirus infections, evaluates the prophylactic treatment experience of retrovirus infections in the animal model, and provides a plausible rationale for treatment intervention of primary HIV-1 infection in humans. Recent work delineating the pathogenesis of primary HIV-1 infection provides insight into the major mechanisms of viral dissemination and host immune response. The results from retrovirus-infected animal models treated with antiviral agents suggests that therapy at the time of viral dissemination may be an effective strategy that may modify disease progression. Clinical trials to evaluate this approach are in progress.
引用
收藏
页码:1490 / 1501
页数:12
相关论文
共 81 条
  • [61] SUPPRESSION OF MOUSE VIREMIA AND RETROVIRAL DISEASE BY 3'-AZIDO-3'-DEOXYTHYMIDINE
    RUPRECHT, RM
    OBRIEN, LG
    ROSSONI, LD
    NUSINOFFLEHRMAN, S
    [J]. NATURE, 1986, 323 (6087) : 467 - 469
  • [62] DEVELOPMENT OF ANTIVIRAL TREATMENT STRATEGIES IN MURINE MODELS
    RUPRECHT, RM
    KOCH, JA
    SHARMA, PL
    ARMANY, RS
    [J]. AIDS RESEARCH AND HUMAN RETROVIRUSES, 1992, 8 (06) : 997 - 1011
  • [63] POSTEXPOSURE PROPHYLAXIS WITH ZIDOVUDINE SUPPRESSES HUMAN-IMMUNODEFICIENCY-VIRUS TYPE-1 INFECTION IN SCID-HU MICE IN A TIME-DEPENDENT MANNER
    SHIH, CC
    KANESHIMA, H
    RABIN, L
    NAMIKAWA, R
    SAGER, P
    MCGOWAN, J
    MCCUNE, JM
    [J]. JOURNAL OF INFECTIOUS DISEASES, 1991, 163 (03) : 625 - 627
  • [64] SINET M, 1992, J ACQ IMMUN DEF SYND, V5, P577
  • [65] SONNERBORG AB, 1989, AIDS, V3, P277, DOI 10.1097/00002030-198905000-00005
  • [66] CD4+ LYMPHOCYTE CELL ENUMERATION FOR PREDICTION OF CLINICAL COURSE OF HUMAN-IMMUNODEFICIENCY-VIRUS DISEASE - A REVIEW
    STEIN, DS
    KORVICK, JA
    VERMUND, SH
    [J]. JOURNAL OF INFECTIOUS DISEASES, 1992, 165 (02) : 352 - 363
  • [67] TAVARES L, 1987, CANCER RES, V47, P3190
  • [68] ZIDOVUDINE IN THE MANAGEMENT OF PRIMARY HIV-1 INFECTION
    TINDALL, B
    GAINES, H
    IMRIE, A
    VONSYDOW, MAE
    EVANS, L
    STRANNEGARD, O
    TSANG, ML
    LINDBACK, S
    COOPER, DA
    [J]. AIDS, 1991, 5 (05) : 477 - 484
  • [69] PRIMARY HIV-INFECTION - HOST RESPONSES AND INTERVENTION STRATEGIES
    TINDALL, B
    COOPER, DA
    [J]. AIDS, 1991, 5 (01) : 1 - 14
  • [70] ADMINISTRATION OF ZIDOVUDINE DURING PRIMARY HIV-1 INFECTION MAY BE ASSOCIATED WITH A LESS VIGOROUS IMMUNE-RESPONSE
    TINDALL, B
    CARR, A
    GOLDSTEIN, D
    PENNY, R
    COOPER, DA
    [J]. AIDS, 1993, 7 (01) : 127 - 128